Resumen de: US2023165890A1

According to the invention, to treat severe progression of viral infections, in particular SARS-CoV-2 infections, heparin or one of its derivatives and/or another pharmaceutically acceptable polyanion is used in therapeutic apheresis, wherein a patient's blood is treated in an extracorporeal circuit such that a) blood cells are separated from plasma, b) a suitable amount of heparin/heparin derivative or pharmaceutically acceptable polyanion is added to the plasma, c) the pH of the plasma is decreased to <6 by means of a suitable buffer, d) precipitated substances are separated out, e) excess heparin and/or polyanion is adsorbed on an adsorber, f) the pH is increased back to the physiological value, and g) the treated plasma together, in parallel or successively with blood cells and, where necessary, a saline solution is reinfused into the patient.

Resumen de: US2023165881A1

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for treating respiratory viral illnesses, such as COVID-19.

Resumen de: US2023165856A1

The present disclosure is directed to the use of dapagliflozin and ambrisentan for the treatment and prevention of coronavirus disease 2019 (COVID-19), SARS-CoV-2 infection, and/or symptoms thereof.

Resumen de: US2023165876A1

T he present invention provides methods of treating COV-ID-19 in a subject using methylthioninium compounds.

Resumen de: US2023165875A1

The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.

Resumen de: US2023165826A1

The present invention is directed to compositions for administration of camostat mesylate or nafamostat mesylate to subjects by inhalational delivery, and to methods of treatment of COVID19 by administering such compositions to subjects by inhalational delivery.

Resumen de: US2023165834A1

Solubilized Alpha Lipoic Acid, solubilized Epigallocatechin 3-gallate, and solubilized Curcumin in combination as therapeutic agent(s) for the prophylaxis and/or treatment of arthritis including, without limitation, fibrotic disease, inflammatory disease, neurodegenerative disease, autoimmune disease, or heart and vascular disease as a consequence of arthritic pathophysiology, and viral infections including SARS-CoV-2 infections. There is also described the use of the solubilized therapeutic agent(s) for oral administration, and for inhalative administration.

Resumen de: US2023165524A1

Systems, devices, and methods are provided to facilitate the implementation of a “proning protocol” to improve a clinical outcome for a person having SARS-CoV-2 (COVID-19) or other condition that may benefit from spending time in the prone position. For example, a system may include a mobile device (e.g., smartphone, tablet, etc.) providing a proning application configured to manage a configuration and implementation of a proning protocol for a person and configured to receive sensor data from (a) a wearable sensor device secured to the person and including sensor(s) (e.g., accelerometer(s)) that monitor the person body position, and/or (b) other sensor(s) that monitor other physiological parameters relative to the proning protocol. The proning application may determine and output feedback to manage the person's position based at least on the received sensor data and defined parameters of the proning protocol.

Resumen de: US2023167601A1

A stable aqueous dispersion containing a mixture of an anionic polymer, quaternary ammonium salt, a dispersion agent and water. The dispersing agent is poly (acrylamide-co-acrylic acid) or copolymer of maleic acid and an olefin. The dispersion can be applied to textile materials and nonwoven substrates. Nonwoven substrates, such as polypropylene substrates can be treated with the dispersion to provide a highly active quick killing antimicrobial effect: Log 4 reduction in 5 minutes. This would be useful to deactivate the SARS-CoV-2 virus, which causes Covid-19.

Resumen de: US2023167511A1

Provided herein is a viral RNA detection system, utilizing the RNA-targeting properties of the optimized Cas13d enzyme, CasRx, to detect SARS-CoV-2 RNA, e.g., synthetic SARS-CoV-2 RNA. The system detects novel target sequences conserved within the actively evolving genome, to provide a panel of diagnostic target sites least likely to result in false negatives due to genomic variation. Successful detection of viral RNA through both a fluorescence-based readout assay as well as a rapid paper dipstick lateral flow assay requiring no specialized laboratory equipment was shown. Low viral titers can be detected within minutes following only minutes of sample processing.

Resumen de: US2023167157A1

Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity,

Resumen de: US2023167159A1

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

Resumen de: US2023167166A1

The present invention provides a variety of methods for the identification and/or treatment of subjects that are at risk for developing life-threatening complications of SARS-CoV-2 infection and other infections. Such methods involve determining if a subject has clonal hematopoiesis.

Resumen de: US2023168249A1

Disclosed herein are recombinant antibodies or the fragment thereof for detecting severe acute respiratory syndrome coronavirus (SARS-CoV). According to some embodiments, the SARS-CoV is SARS-CoV-1. According to some alternative embodiments, the SARS-CoV is SARS-CoV-2. Also disclosed herein are a kit comprising the recombinant antibodies, and a method for diagnosing the infection of SARS-CoV by using the recombinant antibody or the kit.

Resumen de: US2023168245A1

The present disclosure provides a lateral flow device, and methods of use of the device, for accurately and rapidly detecting a COVID-19 infection in a subject. The lateral flow device described herein detects in a liquid sample from the subject the presence or absence of neutralizing and non-neutralizing anti-S1 spike antibodies as IgM and IgG types. The anti-S1 antibodies neutralizing antibodies (e.g., both IgM and IgG) can block binding between ACE2 antigen and S1 spike protein which is the basis for the design of the lateral flow device.

Resumen de: US2023168247A1

Methods of detecting SARS-CoV-2 antibodies with improved specificity are described. The methods can include contacting a sample potentially containing SARS-CoV-2 antibodies with a reagent to remove non-anti-SARS-CoV-2 antibodies, such as a reagent comprising an epitope from a nucleocapsid protein or spike protein of a common coronavirus. The methods can include contacting the sample with a mutant SARS-CoV-2 nucleocapsid protein or spike protein comprising a reduced number of common coronavirus epitopes. The methods can involve comparing results from an immunoassay performed with a SARS-CoV-2 protein to results obtained from immunoassays performed with analogous protein from one or more common coronaviruses.

Resumen de: AU2021375281A1

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

Resumen de: AU2021364100A1

Lateral flow assay (LFA) devices for detecting whether SARS-CoV-2 nucleocapsid protein is present in a sample are provided. Aspects of the LFA devices include: a sample receiving region; a conjugate region downstream from the sample receiving region that includes test particulate labels made up of label particles conjugated to first and second specific binding members that specifically bind to the SARS-CoV-2 nucleocapsid protein; and a detection region downstream from the conjugate region which includes an immobilized capture specific binding member that specifically binds to the SARS-CoV-2 nucleocapsid protein. Also provided are methods of using the LFA devices, as well as readers, systems and kits for use in the same.

Resumen de: AU2021363921A1

The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. This fusion protein includes hemagglutinin and a receptor binding domain of SARS-CoV-2. This vaccine includes said fusion protein.

Resumen de: AU2021355767A1

This invention pertains to biotechnology, more specifically to the field of human health. What is described in particular are covalent conjugates of the SARS-CoV-2 receptor binding domain with a carrier protein, the method used to obtain the conjugates, and the vaccine compositions that contain them. The vaccine compositions described in the present invention are useful for the prevention of the SARS-CoV-2 infection as they induce a strong response of neutralizing antibodies.

Resumen de: WO2023094885A2

Immunogenic peptides, polypeptides, protein subunits, nucleic acids encoding the same, compositions and vaccines containing the immunogenic peptides or nucleic acids, and methods of vaccination and/or treatment of SARS-CoV-2 infection. A serological diagnostic assay as well as a use of the serological assay with peptide P3 (SEQ ID NO: 3) to reveal whether a human suspected to be infected or to have been infected by a SARS-CoV-2 virus has generated an anti SARS-CoV-2 protective immunity.

Resumen de: EP4186922A1

The present invention relates to a binding molecule having neutralizing activity against the coronavirus superfamily. More specifically, the binding molecule of the present invention has excellent binding affinity and excellent neutralizing efficacy against various coronavirus species that may infect humans, including not only wild-type SARS-coronavirus-2 (SARS-CoV-2) and mutant viruses that may occur in the future, but also SARS-coronavirus-1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), etc., which infect humans, causing fatal diseases. Thus, the binding molecule is very useful for the diagnosis, prevention or treatment of diseases caused by coronaviruses.

Resumen de: WO2022020636A2

The present invention relates to severe acute respiratory syndrome coronavirus 2 ("SARS-CoV2") immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.

Resumen de: WO2022045935A1

The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to a nucleic acid that encodes RBD-S of SARS-CoV-2, to an expression cassette and a vector based thereon, as well as to a recombinant AAV5 (adeno-associated virus serotype 5)-based virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.